---
schema_version: "secwatch.filing_event.v1"
accession: "0001040130-24-000114"
form_type: "8-K"
ticker: "PETS"
cik: "0001040130"
company_name: "PETMED EXPRESS INC"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:15:37.218820+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# PetMed Express Q2 FY2025: net sales $59.6M, net income $2.3M, EPS $0.11

## Summary
- Net sales of $59.6M; net income $2.3M ($0.11 diluted EPS) vs $0.7M ($0.03) in prior year.
- Gross margin 29.1% (+0.8% YoY); Adjusted EBITDA $2.1M, sequential improvement from $(1.5)M in Q1.
- CEO cites cost savings from consolidating PetMeds/PetCareRx ops; positioned for growth initiatives.

## SEC filing metadata
- accession: 0001040130-24-000114
- form_type: 8-K
- ticker: PETS
- cik: 0001040130
- company_name: PETMED EXPRESS INC
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1040130/000104013024000114/0001040130-24-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1040130/000104013024000114/pets-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001040130-24-000114
- JSON: https://secwatch.observer/filing/0001040130-24-000114.json
- Plain text: https://secwatch.observer/filing/0001040130-24-000114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.